期刊文献+
共找到7篇文章
< 1 >
每页显示 20 50 100
Micro RNA in inflammatory bowel disease: Translational research and clinical implication 被引量:8
1
作者 Kurt Fisher jingmei lin 《World Journal of Gastroenterology》 SCIE CAS 2015年第43期12274-12282,共9页
Idiopathic inflammatory bowel disease(IBD) predominantly includes ulcerative colitis and Crohn's disease. The pathogenesis of IBD is complex and not completely understood. Micro RNAs belong to a class of noncoding... Idiopathic inflammatory bowel disease(IBD) predominantly includes ulcerative colitis and Crohn's disease. The pathogenesis of IBD is complex and not completely understood. Micro RNAs belong to a class of noncoding small RNAs that post-transcriptionally regulate gene expression. Unique micro RNA expression profiles have been explored in IBD. In this review,we focus on the unique micro RNA expression pattern in both tissue and peripheral blood from IBD patients and emphasize the potential diagnostic and therapeutic applications. The discovery of micro RNAs has contributed to our understanding of IBD pathogenesis and might lead to clinical advance in new therapeutics. 展开更多
关键词 INFLAMMATORY BOWEL disease ULCERATIVE COLITIS CROH
下载PDF
Outcomes of submucosal(T1b) esophageal adenocarcinomas removed by endoscopic mucosal resection 被引量:2
2
作者 Darren D Ballard Neel Choksi +7 位作者 jingmei lin Eun-Young Choi B Joseph Elmunzer Henry Appelman Douglas K Rex Hala Fatima William Kessler John M DeWitt 《World Journal of Gastrointestinal Endoscopy》 CAS 2016年第20期763-769,共7页
AIM To investigate the outcomes and recurrences of p T1 b esophageal adenocarcinoma(EAC) following endoscopic mucosal resection(EMR) and associated treatments.METHODS Patients undergoing EMR with pathologically confir... AIM To investigate the outcomes and recurrences of p T1 b esophageal adenocarcinoma(EAC) following endoscopic mucosal resection(EMR) and associated treatments.METHODS Patients undergoing EMR with pathologically confirmed T1 b EAC at two academic referral centers were retrospectively identified.Patients were divided into 4 groups based on treatment following EMR:Endoscopic therapy alone(group A),endoscopic therapy with either chemotherapy,radiation or both(group B),surgicalresection(group C) or no further treatment/lost to follow-up(<12 mo)(group D).Pathology specimens were reviewed by a central pathologist.Follow-up data was obtained from the academic centers,primary care physicians and/or referring physicians.Univariate analysis was performed to identify factors predicting recurrence of EAC.RESULTS Fifty-three patients with T1 b EAC underwent EMR,of which 32(60%) had adequate follow-up ≥ 12 mo(median 34 mo,range 12-103).There were 16 patients in group A,9 in group B,7 in group C and 21 in group D.Median follow-up in groups A to C was 34 mo(range 12-103).Recurrent EAC developed overall in 9 patients(28%) including 6(38%) in group A(median:21 mo,range:6-73),1(11%) in group B(median:30 mo,range:30-30) and 2(29%) in group C(median 21 mo,range:7-35.Six of 9 recurrences were local;of the 6 recurrences,5 were treated with endoscopy alone.No predictors of recurrence of EAC were identified.CONCLUSION Endoscopic therapy of T1 b EAC may be a reasonable strategy for a subset of patients including those either refusing or medically unfit for esophagectomy. 展开更多
关键词 ESOPHAGEAL cancer SUBMUCOSAL T1b Endoscopic MUCOSAL RESECTION Chemotherapy ESOPHAGECTOMY
下载PDF
Substantial hepatic necrosis is prognostic in fulminant liver failure 被引量:1
3
作者 Paul Ndekwe Marwan S Ghabril +3 位作者 Yong Zang Steven A Mann Oscar W Cummings jingmei lin 《World Journal of Gastroenterology》 SCIE CAS 2017年第23期4303-4310,共8页
AIM To evaluate if any association existed between the extent of hepatic necrosis in initial liver biopsies and patient survival.METHODS Thirty-seven patients with fulminant liver failure, whose liver biopsy exhibited... AIM To evaluate if any association existed between the extent of hepatic necrosis in initial liver biopsies and patient survival.METHODS Thirty-seven patients with fulminant liver failure, whose liver biopsy exhibited substantial necrosis, were identified and included in the study. The histological and clinical data was then analyzed in order to assess the relationship between the extent of necrosis and patient survival, with and without liver transplantation. The patients were grouped based on the etiology of hepatic necrosis. Each of the etiology groups were then further stratified according to whether or not they had received a liver transplant post-index biopsy, and whether or not the patient survived.RESULTS The core tissue length ranged from 5 to 44 mm with an average of 23 mm. Causes of necrosis included 14 autoimmune hepatitis, 10 drug induced liver injury(DILI), 9 hepatitis virus infection, and 4 unknown origin. Among them, 11 showed submassive(26%-75% of the parenchymal volume) and 26 massive(76%-100%) necrosis. Transplant-free survival was worse in patients with a higher extent of necrosis(40%, 71.4% and 100% in groups with necrosis of 76%-100%, 51%-75%and 26%-50%, respectively). Additionally, transplantfree survival rates were 66.7%, 57.1%, and 25.0% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively. Even after liver transplantation, the survival rate in patients as a result of viral hepatitis remained the lowest(80%, 100%, and 40% in groups of autoimmune hepatitis, DILI, and viral hepatitis, respectively).CONCLUSION Adequate liver biopsy with more than 75% necrosis is associated with significant transplant-free mortality that is critical in predicting survival. 展开更多
关键词 Submassive 坏死 巨大的坏死 暴发性的肝失败 肝移植 活体检视 组织病理学说
下载PDF
Validation of American Joint Committee on Cancer 8th edition of TNM staging in resected distal pancreatic cancer 被引量:1
4
作者 Feng Yin Mohammed Saad +17 位作者 Hao Xie jingmei lin Christopher R Jackson Bing Ren Cynthia Lawson Dipti M Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W Schultz Dongwei Zhang Courtney L Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Xiuli Liu 《World Journal of Gastrointestinal Pharmacology and Therapeutics》 CAS 2020年第2期25-39,共15页
BACKGROUND In order to improve risk stratification and clinical management of the pancreatic ductal adenocarcinoma(PDAC),the American Joint Committee on Cancer(AJCC)has published its eighth edition staging manual.Some... BACKGROUND In order to improve risk stratification and clinical management of the pancreatic ductal adenocarcinoma(PDAC),the American Joint Committee on Cancer(AJCC)has published its eighth edition staging manual.Some major changes have been introduced in the new staging system for both T and N categories.Given the rarity of resectable disease,distal pancreatic cancer is likely underrepresented in the published clinical studies,and how the impact of the staging system actually reflects on to clinical outcomes remain unclear.AIM To validate the AJCC 8th edition of TNM staging in distal PDAC.METHODS A retrospective cohort study was performed in seven academic medical centers in the United States.Clinicopathological prognostic factors associated with progression-free survival(PFS)and overall survival(OS)were evaluated through univariate and multivariate analyses.RESULTS Overall,454 patients were enrolled in the study,and were divided into 2 subgroups:Invasive intraductal papillary mucinous neoplasms(IPMN)(115 cases)and non-IPMN associated adenocarcinoma(339 cases).Compared to invasive IPMN,non-IPMN associated adenocarcinomas are more common in relatively younger patients,have larger tumor size,are more likely to have positive lymph nodes,and are associated with a higher tumor(T)stage and nodal(N)stage,lymphovascular invasion,perineural invasion,tumor recurrence,and a worse PFS and OS.The cohort was predominantly categorized as stage 3 per AJCC 7th edition staging manual,and it’s more evenly distributed based on 8th edition staging manual.T and N staging of both 7th and 8th edition sufficiently stratify PFS and OS in the entire cohort,although dividing into N1 and N2 according to the 8th edition does not show additional stratification.For PDAC arising in IPMN,T staging of the 7th edition and N1/N2 staging of the 8th edition appear to further stratify PFS and OS.For PDAC without an IPMN component,T staging from both versions fails to stratify PFS and OS.CONCLUSION The AJCC 8th edition TNM staging system provides even distribution for the T staging,however,it does not provide better risk stratification than previous staging system for distal pancreatic cancer. 展开更多
关键词 Pancreatic cancer Pancreatic ductal adenocarcinoma Prognosis Intraductal papillary mucinous neoplasms Survival American Joint Committee on Cancer
下载PDF
Integrative omics analysis identifies macrophage migration inhibitory factor signaling pathways underlying human hepatic fibrogenesis and fibrosis 被引量:1
5
作者 Zhipeng Liu Naga Chalasani +4 位作者 jingmei lin Samer Gawrieh Yuan He Yan J.Tseng Wanqing Liu 《Journal of Bio-X Research》 2019年第1期16-24,共9页
The genetic basis underlying liver fibrosis remains largely unknown.We conducted a study to identify genetic alleles and underlying pathways associated with hepatic fibrogenesis and fibrosis at the genome-wide level i... The genetic basis underlying liver fibrosis remains largely unknown.We conducted a study to identify genetic alleles and underlying pathways associated with hepatic fibrogenesis and fibrosis at the genome-wide level in 121 human livers.By accepting a liberal significance level of P<1e-4,we identified 73 and 71 candidate loci respectively affecting the variability in alpha-smooth muscle actin(a-SMA)levels(fibrogenesis)and total collagen content(fibrosis).The top genetic loci associated with the two markers were BAZA1 and NOL10 for a-SMA expression and FAM46A for total collagen content(P<1e-6).We further investigated the relationship between the candidate loci and the nearby gene transcription levels(cis-expression quantitative trait loci)in the same liver samples.We found that 44 candidate loci for a-SMA expression and 44 for total collagen content were also associated with the transcription of the nearby genes(P<0.05).Pathway analyses of these genes indicated that macrophage migration inhibitory factor(MIF)related pathway is significantly associated with fibrogenesis and fibrosis,though different genes were enriched for each marker.The association between the single nucleotide polymorphisms,MIF and a-SMA showed that decreased MIF expression is correlated with increased a-SMA expression,suggesting that variations in MIF locus might affect the susceptibility of fibrogenesis through controlling MIF gene expression.In summary,our study identified candidate alleles and pathways underlying both fibrogenesis and fibrosis in human livers.Our bioinformatics analyses suggested MIF pathway as a strong candidate involved in liver fibrosis,thus further investigation for the role of the MIF pathway in liver fibrosis is warranted.The study was reviewed and approved by the Institutional Review Board(IRB)of Wayne State University(approval No.201842)on May 17,2018. 展开更多
关键词 hepatic fibrosis GENOMICS macrophage migration inhibitory factor alpha-smooth muscle actin pathway enrichment analysis genetic susceptibility
原文传递
脾血管浸润是胰体尾癌切除术后的不良预后因素
6
作者 Feng Yin Mohammed Saad +17 位作者 jingmei lin Christopher R.Jackson Bing Ren Cynthia Lawson Dipti M.Karamchandani Belen Quereda Bernabeu Wei Jiang Teena Dhir Richard Zheng Christopher W.Schultz Dongwei Zhang Courtney L.Thomas Xuchen Zhang Jinping Lai Michael Schild Xuefeng Zhang Hao Xie Xiuli Liu 《Gastroenterology Report》 SCIE EI 2021年第2期139-145,I0002,共8页
背景:由于较高的远处转移率,胰体尾癌是致死率最高的肿瘤之一。本研究旨在评估脾血管浸润对于胰体尾癌切除术患者的预后价值。方法:在这项回顾性研究中,我们收集了454例胰体尾癌患者的临床病理资料,通过单因素和多因素分析明确本组患者... 背景:由于较高的远处转移率,胰体尾癌是致死率最高的肿瘤之一。本研究旨在评估脾血管浸润对于胰体尾癌切除术患者的预后价值。方法:在这项回顾性研究中,我们收集了454例胰体尾癌患者的临床病理资料,通过单因素和多因素分析明确本组患者无进展生存(PFS)和总体生存(OS)的预后影响因素,重点关注脾动/静脉浸润的预后价值。结果:单因素分析结果显示,肿瘤较大、非导管内乳头状黏液瘤(non-IPMN)相关的腺癌、低分化、pT3期、淋巴结转移、脉管浸润、神经浸润、病理学脾静脉浸润、影像学脾静脉浸润者PFS和OS均显著缩短(均P<0.05)。多因素分析证实,non-IPMN相关腺瘤、pT3期、pN1-2期及术后辅助化疗是PFS和OS的独立危险因素;此外,肿瘤较大和影像学脾静脉浸润同时也是PFS的独立预后因素。结论:应当就如何检测和报告胰体尾癌手术标本的脾血管状态,形成一个统一的规范。 展开更多
关键词 pancreatic cancer splenic artery splenic vein PROGNOSIS intraductal papillary mucinous neoplasm
下载PDF
接受术后化疗的炎性肠病相关结直肠癌患者的复发率与生存率:一项比较研究
7
作者 Mohannad Dugum jingmei lin +5 位作者 Rocio Lopez Bassam Estfan Elena Manilich Luca Stocchi Bo Shen Xiuli Liu 《Gastroenterology Report》 SCIE EI 2017年第1期57-61,I0002,I0003,共7页
背景与目的:炎性肠病(IBD)患者具有一定结直肠癌发生风险。研究显示,IBD相关结直肠癌与非IBD相关结直肠癌在肿瘤发生机制和组织形态学上存在差异,提示其肿瘤行为和治疗反应也可能有所不同。我们旨在比较接受术后化疗IBD相关与非IBD相关... 背景与目的:炎性肠病(IBD)患者具有一定结直肠癌发生风险。研究显示,IBD相关结直肠癌与非IBD相关结直肠癌在肿瘤发生机制和组织形态学上存在差异,提示其肿瘤行为和治疗反应也可能有所不同。我们旨在比较接受术后化疗IBD相关与非IBD相关的结直肠癌患者肿瘤复发及生存率的差异。方法:检索Cleve?land临床中心结直肠癌数据库,筛选出1994-2010年间的65例IBD相关结直肠癌且接受了术后辅助化疗的患者,排除21例临床资料不完整者。按照年龄、手术目的、肿瘤部位、肿瘤病理分级、AJCC分期和T分期,对IBD相关和非IBD相关的结直肠癌患者进行1:4的病例匹配分组。分别采用竞争风险模型和Cox回归模型来评估IBD对无病生存和总体生存的影响。结果:44例IBD相关和176例非IBD相关的结直肠癌患者完成匹配。在IBD组患者中,29例(66%)为溃疡性结肠炎,14例(19%)为克罗恩病,1例(2%)诊断为不确定型肠炎。IBD平均诊断年龄为(28.1±14.5)岁,IBD诊断至结直肠癌治疗的平均间期为(21.5±12.6)年。10例(23%)IBD组患者出现了肿瘤复发,而非IBD组则有34例(19%)复发(P=0.074)。IBD组与非IBD组患者无瘤生存率(HR=0.60;95%CI:0.35~1.05;P=0.074)和总体生存率(HR=0.87;95%CI:0.54~1.4;P=0.58)的差异均无统计学意义。结论:接受术后化疗的IBD相关结直肠癌患者,其复发率与生存率与非IBD相关结直肠癌患者相当。有必要行进一步的前瞻性研究来证实这些发现,以指导治疗决策。 展开更多
关键词 炎性肠病 结直肠癌 辅助化疗 预后
下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部